Complete Genomics Launches Advanced Sequencing Solutions

Complete Genomics Unveils Innovative Sequencing Solutions
Complete Genomics, a pioneering company in genomic sequencing, has recently introduced its latest advancements in sequencing technology. The company showcased its new DNBSEQ-T1+ and DNBSEQ-E25 Flash products designed to enhance the speed, flexibility, and overall efficiency of genomic research.
DNBSEQ-T1+: Revolutionizing Mid-Throughput Sequencing
The DNBSEQ-T1+ is an advanced mid-throughput sequencer capable of completing paired-end 150 sequencing workflows in just 24 hours while maintaining high Q40 accuracy. This revolutionary device features various flow cell formats which include two to four addressable lanes on each flow cell, as well as dual independent flow cell operation. Such capabilities significantly boost data output and reduce turnaround time, leading to higher efficiency in laboratory processes.
Increased Flexibility and User-Friendly Design
This latest mid-throughput sequencer allows laboratories to reduce their time-to-result, which is critical for many research scenarios. With a throughput range of 25–1,200 Gb and a daily maximum capacity exceeding 1 Tb, the DNBSEQ-T1+ empowers labs with greater data processing potential. Its unique auto-DNB making and loading features simplify the workflow, allowing the processing of multiple samples without requiring barcodes and commencing the sequencing process swiftly, within minutes.
Enhanced Efficiency for Diverse Applications
Rob Tarbox, the VP of Product and Marketing at Complete Genomics, commented on the advantages of the DNBSEQ-T1+. He stated, 'The DNBSEQ-T1+ offers unmatched efficiency, output, and cost-effectiveness compared to older high-output systems, facilitating a myriad of genomic applications including Whole Genome Sequencing, Single Cell, Spatial, Oncology, Rare Disease, and Metagenomics.' This integration of performance and value presents laboratories the needed features for multifaceted genomic tasks.
DNBSEQ-E25 Flash: AI-Powered Portable Sequencer
Alongside the DNBSEQ-T1+, Complete Genomics has introduced the DNBSEQ-E25 Flash. This upgraded portable sequencer leverages AI enhancements to redefine convenience in sequencing. The advanced instrument operates using self-luminescence technology along with a CMOS-based flow cell, optimizing signal intensity and precision through AI-driven design.
Accelerated Sequencing with AI Technology
The DNBSEQ-E25 Flash features an AI-based base calling system powered by an edge device. This system utilizes the NVIDIA Jetson platform to expedite sequencing processes significantly. With the deployment of a single-substrate injection, traditional dual-luciferase systems are bypassed, thus minimizing cycle times to only one minute and achieving SE50 sequencing in under two hours.
Complete Genomics at AGBT 2025
During the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting, Complete Genomics will host a variety of interactive sessions. These will include live demonstrations of the new sequencers and informative presentations designed to highlight the powerful capabilities of DNBSEQ-T1+ and DNBSEQ-E25 Flash in applications ranging from clinical Whole Genome Sequencing to single-cell analysis.
Workshops and Live Demonstrations
The company encourages all attendees to visit its presentations scheduled in Suite Osprey 6 and attend a specialized workshop in the Calusa Ballroom titled 'Advancing Genomics Discoveries with DNBSEQ-T1+', led by renowned experts. This workshop will help participants understand the practical applications of the newly unveiled technology in depth.
About Complete Genomics
Established in 2005, Complete Genomics has played a crucial role in advancing high-throughput, cost-effective sequencing technologies. With a prolific output of over 9,400 publications, the company’s innovative solutions continue to drive the progress of genomic research around the globe.
Frequently Asked Questions
What are the key features of the DNBSEQ-T1+ sequencer?
The DNBSEQ-T1+ sequencer offers mid-throughput capabilities, completing workflows in 24 hours with high accuracy and flexible flow cell formats.
How does the DNBSEQ-E25 Flash utilize AI technology?
The DNBSEQ-E25 Flash employs AI-driven enhancements to improve sequencing speed and signal precision through optimized system designs.
What applications can benefit from the new sequencing solutions?
These sequencing solutions are suitable for various applications including Whole Genome Sequencing, Oncology, Rare Disease studies, and more.
Where will Complete Genomics present its products?
Complete Genomics will showcase their products at the AGBT 2025 General Meeting with live demonstrations and workshops.
What is the significance of these new products for researchers?
These products provide enhanced efficiency, speed, and cost-effectiveness, significantly improving research workflows in genomic studies.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.